請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45210
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林淑文(Shu-Wen Lin) | |
dc.contributor.author | Yu-Ju Tseng | en |
dc.contributor.author | 曾郁茹 | zh_TW |
dc.date.accessioned | 2021-06-15T04:09:00Z | - |
dc.date.available | 2010-03-12 | |
dc.date.copyright | 2010-03-12 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-02-03 | |
dc.identifier.citation | 1. Briefing document for voriconazole US Food and Drug Administration, 2001. (Accessed at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2.htm.)
2. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1840-2. 3. Girmenia C LG, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report. . J Clin Microbial 1998;36:1436-8. 4. Richardson K, A. S. Bell, R. P. Dickinson, S. Narayanaswami, and S. J. Ray. UK-109,496, a novel, wide-spectrum derivative for the treatment of fungal infections: synthesis and SAR. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology; 1995:125. 5. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-4. 6. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7. 7. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999;43:169-71. 8. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998;42:161-3. 9. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 1999;43:1463-4. 10. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008;46:2620-9. 11. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35. 12. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999;37:3946-51. 13. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001;45:605-7. 14. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-8. 15. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998;42:531-3. 16. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002;46:3298-300. 17. Jeu L. Piacenti FJL, A. G. Fung, H. B. Voriconazole. Clin Ther 2003;25:1321-81. 18. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62-8. 19. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001;45:2151-3. 20. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60. 21. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004;39:584-7. 22. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-6. 23. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005;48:246-50. 24. Dannaoui E, Afeltra J, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002;46:2708-11. 25. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90. 26. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2. 27. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53. 28. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63. 29. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56 Suppl 1:10-6. 30. Patterson BE CP. UK-109-496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man(abstract F78). . In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 1995:126. 31. MICROMEDEX@Healthcare series Thomson, 2009. (Accessed at http://library2.mc.ntu.edu.tw/hcs/librarian/PFPUI/uUakiK2YyiqfX.) 32. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84. 33. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58. 34. Background document for the Antiviral Drug Products Advisory Committee meeting October 4, 2001: Voriconazole tablets and voriconazole injection, Pfizer Global Research Q Development NDAs 21-266 and 21-267. . Food and Drug Administration Web site. (Accessed Norvember 4, 2009, at http:/l~fda.gov/ohrms/dockets/a~Oll/briefing/3792b_02_FDA-voriconazole.htm.) 35. SPORANOX® (ITRACONAZOLE) INJECTION Ortho Biotech product, L.P, 2006. (Accessed 26, October, 2009, at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020966s022lbl.pdf.) 36. Abel S, Allan R, Gandelman K, Tomaszewski K, Webb DJ, Wood ND. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig 2008;28:409-20. 37. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 2001;45:2018-22. 38. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000;44:1917-20. 39. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21. 40. 西藥、醫療器材、含藥化妝品許可證查詢. 行政院衛生署. (Accessed 10/26, 2009, at http://203.65.100.151/DO8180A.asp.) 41. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. 42. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54. 43. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15. 44. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34. 45. Voriconazole tablets and voriconazole injection. Food and Drug Administration Web site, 2001. (Accessed June 25, 2009, at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b_02_FDA-voriconazole.htm.) 46. 藥品交互作用資料庫查詢系統. 行政院衛生署, 2004. (Accessed at http://dif.doh.gov.tw/.) 47. Donnelly JP, De Pauw BE. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004;10 Suppl 1:107-17. 48. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7. 49. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35:509-13. 50. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56 Suppl 1:17-23. 51. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587-8. 52. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:2116-20. 53. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998;42:1105-9. 54. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:3165-9. 55. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2. 56. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 57. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71. 58. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008;61:17-25. 59. Child C, ed. The liver and portal hypertension. Philadelphia: Saunders; 1964. 60. Pugh RN M-LI, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. The British journal of surgery 1973;60:646-9. 61. Cockcroft DW GM. Prediction of creatinine clearance from serum creatinine Nephron 1976;16:31-41. 62. Gault MH LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine Nephron 1992;62:249-56. 63. Schwartz GJ HG, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine Pediatrics 1976;58 259-63. 64. Schwartz GJ FL, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984;104:849-54. 65. Brion LP FA, McCarton C, Schwartz GJ. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J Pediatr 1986;109:698-707. 66. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005;9:R191-9. 67. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004;170:621-5. 68. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. 69. Foundation NK. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. AmJ Kidney Dis 2002;39(2 Suppl 2):S1-266. 70. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 2007;33:1694-703. 71. SC. S. Empiric antibiotic therapy for granulocytopenic cancer patients. . Am J Med 1986;80:13-20. 72. Valles J, Calbo E, Anoro E, et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008;56:27-34. 73. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16. 74. Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int J Antimicrob Agents 2008;32 Suppl 2:S119-23. 75. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506. 76. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93. 77. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27. 78. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4. 79. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. 80. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21. 81. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008;47:674-83. 82. Naranjo CA BU, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. 83. Serious adverse events definitions: National Cancer Insitute online guidelines 2006. . National Cancer Institute. (Accessed 01/06, 2010, at http://ctep.cancer.gov/reporting/ctc.html.) 84. NCI D, NIH, DHHS. Common toxicity criteria version 4.0. In. National Institutes of Health: Bethesda; 2009. 85. Tatro DS. Drug Interaction FactsTM THE AUTHORITY ON DRUG INTERATIONS 2010. St. Louis: Wolters Kluwer Health; 2009. 86. Denning DW. Principles and Practice of Infectious Disease. In: Mandell G DJ, Bennett D, ed. Aspergillus species. Philadelphia: Churchill Livingstone; 2000. 87. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802. 88. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56 Suppl 1:56-61. 89. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31. 90. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56 Suppl 1:37-44. 91. Vehreschild JJ, Bohme A, Reichert D, et al. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol 2008;87:126-31. 92. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002;51:288-96. 93. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-82. 94. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62. 95. Imataki O, Ohnishi H, Kitanaka A, Kubota Y, Ishida T, Tanaka T. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population. Int J Hematol 2008;88:3-6. 96. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71. 97. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-43. 98. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136:739-42. 99. Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008;1:217-20. 100. Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004;53:113-4. 101. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34. 102. Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM. Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage. Br J Clin Pharmacol 2009;68:462-3. 103. Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 2009;15:175-82. 104. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer 2009;52:298-300. 105. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56 Suppl 1:24-9. 106. Andes D, Pascual A, Marchetti O. Antifungal Therapeutic Drug Monitoring - Established and Emerging Indications. Antimicrob Agents Chemother 2008. 107. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008;30:403-11. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45210 | - |
dc.description.abstract | 背景:
Voriconazole是新一代廣效性三唑類抗黴菌藥,在2002年通過美國食品藥物管理局的許可,2003年通過我國衛生署的藥品許可證,治療的適應症為侵入性麴菌感染、念珠菌黴菌血症、念珠菌食道感染、及其他的嚴重黴菌感染。一般來說voriconazole的耐受性良好,但仍有少數嚴重的藥物不良反應被報告,此外,voriconazole由肝臟酵素代謝,且會抑制CYP 2C19、CYP2C9和CYP3A4,會與多種藥品產生藥品交互作用。Voriconazole屬於相對新的抗黴菌藥品,臨床上使用的經驗較少,因此本研究藉由回溯性分析的方式,了解voriconazole的使用現狀。 研究目的: 分析voriconazole的處方型態,例如:使用劑量、劑型、途徑、適應症的適當性;並且評估voriconazole的臨床治療反應、藥物不良反應與病人特質、處方型態之關係。並且記錄可能與voriconazole相關的藥品交互作用。 研究設計、地點、對象: 此研究地點於國立臺灣大學醫學院附設醫院進行收案,為單中心,回溯性病例分析之研究。研究對象則從西元2008年1月1日至2008年12月31日期間在研究地點中有開方voriconazole的病人。 研究方法: 以個案報告表記錄紙本病歷及電子病歷之資料,包括病人基本資料、合併症、黴菌感染危險因子、實驗室檢驗值、適應症、給藥方式、潛在藥品交互作用、藥品不良反應等相關變項。在結束voriconazole治療時,由一名感染專科醫師評估臨床治療反應,並且探討治療效果與病人特質、處方型態之間的關係;若在治療期間發生疑似voriconazole引起的藥品不良反應,利用Naranjo Scale評估voriconazole引起藥品不良反應的可能性,也將探討是否有潛在的危險因子存在會增加藥物不良反應的發生率。檢定兩組之間是否有差異的統計方法包含Student’s t test、Mann-Whitney U Test、和χ2 test;利用羅吉斯迴歸分析尋找影響臨床反應以及增加藥品不良反應的危險因子。 研究結果: 本研究收入了94位病人在2008年於本院使用voriconazole治療黴菌感染,共有105次voriconazole治療療程。病人平均年齡44.3±21.12歲,男性比例佔56.4%。68.1%(64/94)的病人之潛在疾病為血液腫瘤,2位病人沒有任何潛在疾病。在105次治療療程中,有16.2%(17/105)是被證實的侵入性黴菌感染,30.4%(32/105)極有可能為侵入性黴菌感染,45.7%(48/105)的療程治療可能的侵入性黴菌感染,2.9%作為經驗性療法,4.8%則無法確定voriconazole的適應症。 105次的療程中共有54.3%(57/105)的比例,以voriconazole作為黴菌感染的初始治療,而救援治療則最常作為amphotericin B的替代療法。32.4%(34/105)在起始治療時選擇注射劑型,其中只有5.9%(2/34)的病人沒有依仿單建議給予速效劑量。病人平均的維持劑量為3.8 ± 1.18 mg/kg(口服),3.7 ± 0.76 mg/kg(注射)。Voriconazole的治療時間中位數為29天(1-701天)。 Voriconazole臨床治療反應的結果,其中29.5%(31/105)的療程評估為complete response,28.6%(30/105)為partial response,其餘39%(41/105)病人則評估為治療效果不佳,其中有10.5%(11/105)的病人死亡,1位病人失去追蹤。在105次療程中有41次(39%)療程中出現藥品不良反應,共發生55種品項之不良反應,由voriconazole引起之可能性評估結果為,3件(5.5%)為確定,24件(43.6%)為極有可能,28件(50.9%)為可能;其中最常發生的副作用為肝臟酵素異常,發生率高達26.6%(28/105)。藥物不良反應的發生與病人特質、處方型態、臨床反應均無相關。在voriconazole治療期間併用最多的潛在交互作用的藥品為prednisolone(16/105,15.2%),但仍可能併用到配伍禁忌的藥品(6/105,5.7%),例如:carbamazepine、ergonovine、rifampin。在併用潛在交互作用的療程中,20%(21/105)疑似發生藥物不良反應。 不同適應症對於臨床治療反應的結果並無統計上顯著差異(p-value = 0.35),但是羅吉斯回歸模式得到在進入試驗前病人有置入導尿管以及沒有使用白血球生成素的病人會增加voriconazole治療失敗的機率。 結論: 在以血液腫瘤為主的病人群中,voriconazole主要治療可能的侵入性黴菌感染(45.7%),且通常作為salvage therapy的角色,以口服治療為主。整體來說,本院voriconazole的處方型態符合文獻中建議的使用方式。有關voriconazole臨床治療反應,有58.1%的比例治療反應良好(complete response or partial response),最常見之副作用為肝臟酵素異常,發生率高達26.6%。 | zh_TW |
dc.description.abstract | Background:
Voriconazole is a new generation triazole antifungal agent. It was approved by FDA in 2002 and Department of Health in Taiwan in 2003. Its indications include invasive aspergillosis, candidemia, esophageal candidiasis, and other mold infections due to Scedosporium apiospermum and Fusarium spp. Voriconazole is generally considered well tolerated, however, some severe adverse events have been reported. It plays an important role in the drug-drug interactions due to being substrate and inhibitors of CYP2C19, CYP2C9 and CYP3A4. The interactions may interfere in the clinical response and safety of voriconazole. Objective: This retrospective study attempted to describe the prescribing pattern of voriconazole, eg., voriconazole dosage, administration route, and indications. The relationship between clinical response and prescribing pattern was evaluated. Adverse events (AEs) potential caused by voriconazole, and risk factors would be discussed. Methods The study was a retrospective chart review. Patients who were treated with voriconazole in the National Taiwan University Hospital (NTUH) during 01/01~12/31/2008 were included. Patients’ data were collected from medical records and the computerized databases in the hospital, including patients’ demographic data, risk factors of fungal infections, laboratory data, indication for voriconazole, dosing regimen, drug interactions, adverse events, etc. We evaluated the clinical response upon discontinuation of voriconazole and 8 weeks after. Furthermore, we discussed the association between clinical response and patients’ characteristics and prescribing pattern. We also reviewed voriconazole associated AEs and assessed the probability with Naranjo Scale. The statistical methods included Student’s t test, Mann-Whitney U Test, and χ2 test. The logistic regression model was used to identify the risk factors of poor response and adverse events. Result The study included 94 patients and there were 105 treatment courses. The average age was 44.3±21.12 years old. Male accounted for 56.4%. Almost 70% patients (64/94) had hematological malignancies, 2 patients didn’t have any underlying disease. Voriconazole was indicated for the treatment of proven, probable, possible invasive fungal infections in 16.2%, 30.4%, and 45.7% of patients, respectively. But 5 patients were treated with voriconazole without evidence of fungal infection. Voriconzole was used as primary therapy in 54.3% of patients. Among 34 patients (32.4%) treated with IV voriconazole as initial therapy, 5.9% of patients (2/34) didn’t receive the loading dose. Average maintenance doses were 3.8 ± 1.18 mg/kg (oral) and 3.7 ± 0.76 mg/kg (IV). The median course duration was 29 (1~701) days. In terms of response, 29.5%, 28.6%, 39% of patients had complete response, partial response, and no response to voriconazole respectively. One patient lost to follow up. One tenth of patients died during voriconazole therapy with fungal infections. AEs occurred in 41 treatment courses (39 %). Because some patients had ≧ 1 adverse events, there were a total of 55 adverse events. Three AEs were considered as definite, 24 AEs as probable and 28 AEs as possible. The most common side effect was liver function abnormality (28/105, 26.7%). However, adverse events had no association between patients’ characteristics and prescribing pattern. The most common potential drug-drug interaction was involved prednisolone (16/105, 15.2%). There were also 6 treatment courses combined the contraindicated drugs, such as carbamazepine, ergonovine and rifampin. Approximately 20% of AEs (21/105) might be associated with drug-drug medicines. There was no difference between indications and clinical response (p-value = 0.35). In the logistic regression, if patients were on foley catheter and without G-CSF therapy before voriconazole therapy, the risk of treatment failure would be increased. Conclusion In this retrospective study, majority patients had hematological malignancies. Voriconazole was usually indicated for possible invasive fungal infections (45.7%) and as a salvage therapy. Most of patients were treated with oral formulation. In general, the administration of voriconazole in this study was consistent with clinical recommendation. Approximately 58% of patients had good response to voriconazole and the most common adverse event was live enzymes abnormality (26%). There were also 6 treatment courses combined the contraindicated drugs. Approximately 20% of AEs might be associated with drug-drug interactions. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:09:00Z (GMT). No. of bitstreams: 1 ntu-99-R96451004-1.pdf: 2143687 bytes, checksum: afad86b84ad66f92a40d66a70fdec51f (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract v 目錄 viii 圖目錄 x 表目錄 xi 第一章 緒論 1 第二章 文獻探討 2 第1節 Voriconazole之藥理學 2 第2節 抗黴菌效力 3 第3節 Voriconazole藥物動力學 7 第4節 藥效學 12 第5節 適應症 13 第6節 麴菌感染治療指引及重要臨床試驗 13 第7節 安全性與副作用 18 第8節 藥品交互作用 20 第9節 注意事項 30 第10節 Voriconazole的劑量及用法 30 第11節 監測藥品濃度(therapeutic drug monitoring) 31 第三章 研究目的 33 第四章 研究方法 34 第1節 研究架構 34 第2節 研究對象、地點及納入條件 36 第3節 資料收集 37 第4節 統計方法 49 第五章 研究結果 50 第1節 描述性統計 50 第2節 統計檢定 81 第3節 羅吉斯迴歸模型(logistic regression model) 96 第六章 討論 98 第1節 納入條件 98 第2節 病人潛在疾病 98 第3節 黴菌培養結果 99 第4節 適應症 99 第5節 處方型態 100 第6節 臨床治療反應 101 第7節 藥物不良反應 103 第8節 藥品交互作用 108 第9節 研究限制 110 第七章 未來展望 112 第八章 結論 113 第九章 參考資料 114 附件一 個案報告表 121 | |
dc.language.iso | zh-TW | |
dc.title | 某醫學中心 Voriconazole 使用現狀之回溯性研究 | zh_TW |
dc.title | A Retrospective Analysis for the Safety and Effectiveness of Voriconazole in a Medical Center in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.oralexamcommittee | 林慧玲(Fe-Lin Lin),陳宜君(Yee-Chun Chen) | |
dc.subject.keyword | 黴飛,侵入性黴菌感染,藥品使用評估,治療反應,藥物不良反應,藥品交互作用, | zh_TW |
dc.subject.keyword | voriconazole,invasive fungal infection,drug utilization evaluation,treatment response,adverse event,drug-drug interaction, | en |
dc.relation.page | 130 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-02-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 2.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。